| CRL |
Report |
Operating EPS (Q2 2026) |
BEAT |
pred ~$2.90 vs. cons $2.751 |
MEDIUM |
| CRL |
Report |
DSA Book-to-Bill (Q2 2026) |
BEAT |
pred ~1.07x vs. cons 0.993x |
MEDIUM |
| CRL |
Report |
Total Revenue (Q2 2026) |
IN-LINE |
pred ~$987M vs. cons $979.9M |
MEDIUM |
| CRL |
Guide |
FY 2026 Non-GAAP EPS (FY 2026) |
BETTER |
guide ~$11.00-$11.50 mid ~$11.25 vs. cons $11.077 |
MEDIUM |
| CRL |
Guide |
FY 2026 Organic Revenue (FY 2026) |
UNCHANGED |
guide -0.5% to -1.0% vs. cons -0.41% |
MEDIUM |
| CRL |
Guide |
DSA H2 Organic Growth - qualitative (H2 2026) |
UNCHANGED |
reaffirm return to growth; 3 consecutive quarters above 1.0x book-to-bill cited |
MEDIUM |
| CRL |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.0% |
— |
MEDIUM |
| CRL |
Return |
5-day cumulative residual |
+5.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — FY raise is coherent (no implicit Q3+Q4 cut); sell-side revises Q3/Q4 EPS up; short covering provides a modest bid; Investor Day in September keeps the multiple supported |
MEDIUM |